Get the latest news, insights, and market updates on TYRA (Tyra Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: Feb 19, 2026 - $TYRA
Tyra Biosciences price target raised to $53 from $37 at Wedbush
Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratinib in achondroplasia, providing validation for FGFR3 inhibition as an on-target mechanism for height velocity increases in skeletal dysplasia patients. Wedbush views this data as particularly encouraging for dabogratinib, as a more selective FGFR3 inhibitor will Feb 14, 2026 - $TYRA
Does Tyra Biosciences (TYRA) Index Inclusion Mark a Turning Point in Its Institutional Story?
Tyra Biosciences was added to the S&P Biotechnology Select Industry Index on December 13, 2025, marking its inclusion alongside a broader group of U.S.-listed biotech peers. This milestone, alongside a recent planned share sale by a major director who still holds a very large stake, highlights growing institutional attention while insider ownership remains substantial. We’ll now examine how Tyra’s inclusion in the S&P Biotechnology Select Industry Index shapes its investment narrative and... Dec 25, 2025 - $TYRA
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer. Together, Mr. Ashar and Ms. Faulds will be essential in advancing oral dabogratinib through global Phase 2 studies Dec 1, 2025 - $TYRA
Tyra Biosciences Announces Participation at Upcoming Investor Events
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events: Nov 12, 2025 - $TYRA
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent corporate progress. Nov 5, 2025 - $TYRA
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib is a potential first-in-class, once-daily oral FGFR3 selec Aug 21, 2025 - $TYRA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple